Key facts
- This page summarizes Kevin J. Appelbaum's Form 4 filing for Better Therapeutics, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Apr 2022, 16:27.
Kevin J. Appelbaum - 31 Mar 2022 Form 4 Insider Report for Better Therapeutics, Inc.
- Reporting relationship
- Chief Executive Officer, Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 31 Mar 2022
- Net transaction value
- +$4,921
- SEC form
- 4
- Accepted by SEC
- 04 Apr 2022, 16:27:26 UTC
- Prior SEC filing
- 22 Dec 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Heinen, Attorney-in-Fact for Kevin J. Appelbaum
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Kevin J. Appelbaum filed Form 4 for Better Therapeutics, Inc. on 04 Apr 2022.
Change
- Previous filing in this sequence was filed on 22 Dec 2021.
- Current net transaction value: +$4,921.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BTTX
transaction
Common Stock
Purchase
- Transaction value
- $4,921
- Shares
- +2,500
- Change %
- +67%
- Price
- $1.97
- Shares after
- 6,250
- Date
- 31 Mar 2022
- Ownership
- Direct
- Footnotes
- F1
BTTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,406,719
- Date
- 31 Mar 2022
- Ownership
- By Trust
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BTTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +235,000
- Change %
- Price
- $0.000000
- Shares after
- 235,000
- Date
- 01 Apr 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 235,000
- Exercise price
- $1.97
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.96 to $1.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Footnote F2
These shares are owned directly by Kevin Appelbaum, or his successor(s), as Trustee of the Kevin Appelbaum Revocable Trust under Revocable Trust Declaration dated May 16, 2020, as amended (the "Trust"), and indirectly by Mr. Appelbaum as trustee of the Trust. Mr. Appelbaum is an officer, director and ten percent owner of the Issuer.
Footnote F3
The stock option vests as to 1/4 of the shares subject to the stock option on April 1, 2023 and the remaining shares vest in 36 equal monthly installments thereafter, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. The stock option was granted on April 1, 2022.